Aravind Veerapandiyan MD

Pediatric Neurologist/ Neuromuscular Neurologist
#duchenne #LGMD #SMA #CMT
#childneurology
#pediatricneuromuscular
#neuromuscular
#arkansaschildren's

[Aravind Veerapandiyan MD @pandaneuro]

@Aetna @NuvanceHealth Hours on hold and endless transfers, yet no clear answer on why an FDA approved therapy for #DMD is being denied. Repeated denials, no scientific reasoning, and no access to medical director leadership to have meaningful conversations. DMD deserves better!!

[pedneurojournal @pedneurojournal]

Short Communication:
Acute Liver Injury (ALI) Following Delandistrogene Moxeparvovec (DM) Gene Therapy Requiring Intravenous Immunoglobulin (IVIG)

Read more about management of this serious adverse effect (SAE) -- https://t.co/IUFmper72p

#GeneTherapy #DuchenneMuscularDystrophy

[Aravind Veerapandiyan MD @pandaneuro]

@suzmatMD @oabdulhamid Great to be part of this. @pedneurojournal

[Parent Project Muscular Dystrophy (PPMD) @ParentProjectMD]

PPMD is excited to share that a consensus statement providing insights from clinicians who care for patients with #Duchenne into the current therapeutic landscape and access to novel therapies has been published in the Annals of Child Neurology Society. https://t.co/8RCyhNncEa

[Aravind Veerapandiyan MD @pandaneuro]

Another milestone for DMD!
#duchenne #DMD
https://t.co/RODrtsnCbZ

[Aravind Veerapandiyan MD @pandaneuro]

@LakhotiaNeuro @BCBSM This is a absurd. How come this is experimental ????
Approved by FDA for DMD Boys 4 and 5 years old.

[Parent Project Muscular Dystrophy (PPMD) @ParentProjectMD]

Every day, barriers are being broken by individuals across the #Duchenne community, including healthcare providers. How are you breaking barriers? Share your story this #duchenneactionmonth and learn about the quality care CDCCs provide: https://t.co/hqxZDj7IOB

[Muscular Dystrophy News Today @mdnewstoday_]

Pamrevlumab failed to meet LELANTOS-2's main goal of improved motor skills in boys, 6-11, with Duchenne muscular dystrophy and able to walk. https://t.co/gHwB0JjtKp

[Aravind Veerapandiyan MD @pandaneuro]

https://t.co/75JELPQIDr

[Aravind Veerapandiyan MD @pandaneuro]

https://t.co/75JELPQIDr

[Parent Project Muscular Dystrophy (PPMD) @ParentProjectMD]

Today is an incredible milestone for the entire #Duchenne community. Today, the FDA has granted accelerated approval to ELEVIDYS, a micro-dystrophin gene therapy used to treat people ages 4-5 with Duchenne muscular dystrophy. https://t.co/dBrS2KepyD

[Sarepta Therapeutics @Sarepta]

NEWS: SRPT today shared a program update related to SRP-9001. Read our press release:
https://t.co/ateY4r8U5E

[Entrada Therapeutics @entradatx]

We are proud to announce the launch of the Entrada DREAMS Grant Program, an initiative to fund efforts within the #Duchenne muscular dystrophy community that better identify, understand and reach those who are underrepresented or underserved: https://t.co/fTVKZRz2vu.

Thread 1/5

[Parent Project Muscular Dystrophy (PPMD) @ParentProjectMD]

Thank you to everyone who raised their voices today to deliver a clear message about the importance of #genetherapy and its relevance to treatments for #Duchenne. Our community stands ready to support the continuing progress on SRP-9001’s ongoing review: https://t.co/2vZDPm49Px

[Sarepta Therapeutics @Sarepta]

NEWS: An update on the outcome of today’s FDA Advisory Committee Meeting on SRP-9001, our investigational gene therapy for Duchenne muscular dystrophy. Read more here: https://t.co/diKbD8cIGC

[Muscular Dystrophy Association @MDAorg]

Given the increasing momentum with gene therapies, the @US_FDA's Peter Marks, M.D., Ph.D, shared what it takes to turn these therapies into reality and noted the impact of sharing updates with the diverse clinical community at the #MDAconference. Read more in @neurology_live.